Table 2.
Influence of orally administered Hp-ACG on the survival rate of BALB/c mice (8.41 ± 0.31 g) infected with HSV-1/L2
| Compound | Route of administration and dose of the drug |
No. of survivors/ total no. animals in the group |
Mortality, % | Protection, % | MDD days | Yield of virus in brain, lg PFU/ml |
|---|---|---|---|---|---|---|
| –(virus control) | - | 26/60 | 56.67 ± 3.33 | - | 11.35 ± 1.11 | 4.18 ± 0.18 |
| Hp-ACG | 300 mg/kg × 2 times daily/5 days | 29/40 | 27.50 ± 2.50 | 29.17 | 16.40 ± 1.15 | 3.06 ± 0.12 |
| Hp-ACG | 400 mg/kg × 2 times daily/5 days | 33/40 | 17.50 ± 2.50 | 39.17 | 18.13 ± 1.00 | 2.56 ± 0.05 |
| Hp-ACG | 500 mg/kg × 2 times daily/5 days | 37/40 | 7.50 ± 2.50 | 49.17 | 19.78 ± 0.69 | 2.03 ± 0.15 |
| ACV | 100 mg/kg × 2 times daily/5 days | 14/40 | 35 ± 0 | 21.67 | 15.05 ± 1.30 | 3.45 ± 0.05 |
Note. The infectious doseis 4×106 PFU/mouse (titer of virus-containing material 7.30 lg PFU/ml). The results of two independent experiments are presented.